
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
ImpediMed Limited is a medical devices business based in Australia. ImpediMed shares (IPD) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. ImpediMed has a trailing 12-month revenue of around $5.7 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
Since the stock market crash in March caused by coronavirus, ImpediMed 's share price has had significant negative movement.
Its last market close was $0.082, which is 21.90% down on its pre-crash value of $0.105 and 115.79% up on the lowest point reached during the March crash when the shares fell as low as $0.038.
If you had bought $1,000 worth of ImpediMed shares at the start of February 2020, those shares would have been worth $434.78 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $713.04.
52-week range | $0.032 - $0.225 |
---|---|
50-day moving average | $0.0729 |
200-day moving average | $0.0647 |
Target price | $1.16 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.064 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$0.082 on 2020-10-22
1 week (2021-01-07) | -34.40% |
---|---|
1 month (2020-12-17) | -34.40% |
3 months (2020-10-16) | 1.23% |
6 months (2020-07-17) | 20.59% |
1 year (2020-01-16) | -51.76% |
---|---|
2 years (2019-01-16) | -56.36% |
3 years (2018-01-16) | -90.99% |
5 years (2016-01-15) | -92.10% |
Revenue TTM | $5.7 million |
---|---|
Gross profit TTM | $4.1 million |
Return on assets TTM | -57.31% |
Return on equity TTM | -99.09% |
Profit margin | 0% |
Book value | 0.027 |
Market capitalisation | $83.1 million |
TTM: trailing 12 months
We're not expecting ImpediMed to pay a dividend over the next 12 months.
ImpediMed 's shares were split on a 102:100 basis on 1 June 2009. So if you had owned 100 shares the day before before the split, the next day you'd have owned 102 shares. This wouldn't directly have changed the overall worth of your ImpediMed shares – just the quantity. However, indirectly, the new 2% lower share price could have impacted the market appetite for ImpediMed shares which in turn could have impacted ImpediMed 's share price.
Over the last 12 months, ImpediMed 's shares have ranged in value from as little as $0.032 up to $0.225. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while ImpediMed 's is 2.2297. This would suggest that ImpediMed 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.